Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy

Human Gene Therapy

Volumn 22, Issue 4, 2011, Pages 389-404

  Quirin, Christina ^a,b,c   Rohmer, Stanimira ^a,b,c   Fernández Ulibarri, Inés ^a,b   Behr, Michael ^a,b   Hesse, Andrea ^b   Engelhardt, Sarah ^a,b   Erbs, Philippe ^d   Enk, Alexander H ^b   Nettelbeck, Dirk M ^a,b,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCYTOSINE; HYBRID PROTEIN; LUCIFERASE; MONOPHENOL MONOOXYGENASE; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE FUSION PROTEIN;

ARTICLE; BYSTANDER EFFECT; CONTROLLED STUDY; CYTOTOXICITY; GENE CONTROL; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE INSERTION; GENE INSERTION SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNAL RIBOSOME ENTRY SITE; MELANOMA; RNA SPLICING; TRANSGENE; VIRUS REPLICATION;

ADENOVIRIDAE; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; BYSTANDER EFFECT; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE ORDER; GENES, VIRAL; GENETIC VECTORS; HEK293 CELLS; HUMANS; MELANOMA; MONOPHENOL MONOOXYGENASE; MUTAGENESIS, INSERTIONAL; ONCOLYTIC VIRUSES; PRODRUGS; PROMOTER REGIONS, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; TRANSCRIPTION, GENETIC; TRANSGENES;

ADENOVIRIDAE;

EID: 79954490991     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.100     Document Type: Article

References (47)

1. Aboody, K.S., Najbauer, J., Schmidt, N.O., et al. (2006). Targeting of melanoma brain metastases using engineered neural stem/ progenitor cells. Neuro-Oncol. 8, 119-126. (Pubitemid 46542656)
2. Alemany, R., Balague, C., and Curiel, D.T. (2000). Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723-727. (Pubitemid 30460686)
3. Banerjee, N.S., Rivera, A.A., Wang, M., et al. (2004). Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter- driven E1A, E4, or both in submerged cells and organotypic cultures. Mol. Cancer Ther. 3, 437-449. (Pubitemid 39193721)
4. Berget, S.M., Moore, C., and Sharp, P.A. (1977). Spliced segments at the 5' terminus of adenovirus 2 late mRNA. Proc. Natl. Acad. Sci. U.S.A. 74, 3171-3175. (Pubitemid 8180310)
5. Boukamp, P., Petrussevska, R.T., Breitkreutz, D., et al. (1988). Normal keratinization in a spontaneously immortalized an-euploid human keratinocyte cell line. J. Cell Biol. 106, 761-771. (Pubitemid 18089976)
6. Cao, X., Ju, D.W., Tao, Q., et al. (1998). Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitu-mor response in tumor-bearing mice. Gene Ther. 5, 1130-1136. (Pubitemid 28401316)
7. Carette, J.E., Graat, H.C., Schagen, F.H., et al. (2005). Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J. Gene Med. 7, 1053-1062. (Pubitemid 41195067)
8. Cascante, A., Abate-Dage, D., Garcia-Rodriguez, L., et al. (2007). GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model. Gene Ther. 14, 1471-1480. (Pubitemid 47500650)
9. Chow, L.T., Gelinas, R.E., Broker, T.R., and Roberts, R.J. (1977). An amazing sequence arrangement at the 5' ends of adeno-virus 2 messenger RNA. Cell 12, 1-8. (Pubitemid 8193727)
10. Davis, J.J., Wang, L., Dong, F., et al. (2006). Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic ad-enovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther. 13, 720-723. (Pubitemid 44264475)
11. Dias, J.D., Liikanen, I., Guse, K., et al. (2010). Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin. Cancer Res. 16, 2540-2549.
12. Donnelly, M.L., Luke, G., Mehrotra, A., et al. (2001). Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: A putative ribosomal 'skip.' J. Gen. Virol. 82, 1013-1025. (Pubitemid 32454602)
13. Erbs, P., Regulier, E., Kintz, J., et al. (2000). In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 60, 3813-3822. (Pubitemid 32204573)
14. Fang, J., Qian, J.J., Yi, S., et al. (2005). Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23, 584-590. (Pubitemid 41724897)
15. Foloppe, J., Kintz, J., Futin, N., et al. (2008). Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 15, 1361-1371.
16. Fuerer, C., and Iggo, R. (2004). 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther. 11, 142-151. (Pubitemid 38159686)
17. Fueyo, J., Gomez, M.C., Alemany, R., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12. (Pubitemid 30066345)
18. Funston, G.M., Kallioinen, S.E., de Felipe, P., et al. (2008). Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping. J. Gen. Virol. 89, 389-396. (Pubitemid 351622436)
19. Gazit, Z., Weiss, D.W., Shouval, D., et al. (1992). Chemo-adop-tive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. Cancer Immunol. Immunother. 35, 135-144.
20. He, T.C., Zhou, S., da Costa, L.T., et al. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514. (Pubitemid 28145972)
21. Heise, C., Hermiston, T., Johnson, L., et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139.
22. Hermiston, T.W., and Kuhn, I. (2002). Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 9, 1022-1035. (Pubitemid 35462564)
23. Jin, F., Kretschmer, P.J., and Hermiston, T.W. (2005). Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol. Ther. 12, 1052-1063. (Pubitemid 41723039)
24. Johnson, L., Shen, A., Boyle, L., et al. (2002). Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1, 325-337. (Pubitemid 41039135)
25. Krasnykh, V.N., Mikheeva, G.V., Douglas, J.T., and Curiel, D.T. (1996). Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70, 6839-6846. (Pubitemid 26307395)
26. Kucerova, L., Matuskova, M., Pastorakova, A., et al. (2008). Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J. Gene Med. 10, 1071-1082.
27. Liu, Y., and Deisseroth, A. (2006). Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther. 13, 845-855.
28. Liu, Y., Ye, T., Sun, D., et al. (2006). Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes. Gene Ther. 13, 1235-1243. (Pubitemid 44184717)
29. Lukashev, A.N., Fuerer, C., Chen, M.J., et al. (2005). Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum. Gene Ther. 16, 1473-1483. (Pubitemid 41829022)
30. Neefe, J.R., and Glass, J. (1991). Abrogation of interferon-induced resistance to interferon-activated major histocompatibility complex-unrestricted killers by treatment of a melanoma cell line with 5-fluorouracil. Cancer Res. 51, 3159-3163.
31. Nettelbeck, D.M. (2008). Cellular genetic tools to control onco-lytic adenoviruses for virotherapy of cancer. J. Mol. Med. 86, 363-377.
32. Nettelbeck, D.M., Jerome, V., and Muller, R. (1999). A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Ther. 6, 1276-1281. (Pubitemid 29359021)
33. Nettelbeck, D.M., Rivera, A.A., Balague, C., et al. (2002). Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 62, 4663-4670.
34. Ottolino-Perry, K., Diallo, J.S., Lichty, B.D., et al. (2010). Intelligent design: Combination therapy with oncolytic viruses. Mol. Ther. 18, 251-263.
35. Portsmouth, D., Hlavaty, J., and Renner, M. (2007). Suicide genes for cancer therapy. Mol. Aspects Med. 28, 4-41.
36. Rivera, A.A., Wang, M., Suzuki, K., et al. (2004). Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 320, 121-134. (Pubitemid 38296719)
37. Robinson, K.A., Ball, L.E., and Buse, M.G. (2007). Reduction of O-GlcNAc protein modification does not prevent insulin resistance in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 292, E884-E890. (Pubitemid 46411068)
38. Rodriguez, R., Schuur, E.R., Lim, H.Y., et al. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563. (Pubitemid 27283756)
39. Ryan, R.F., Krementz, E.T., and Litwin, M.S. (1988). A role for topical 5-fluorouracil therapy in melanoma. J. Surg. Oncol. 38, 250-256.
40. Sauthoff, H., Pipiya, T., Chen, S., et al. (2006). Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53. Cancer Gene Ther. 13, 686-695. (Pubitemid 44264472)
41. Sauthoff, H., Pipiya, T., Heitner, S., et al. (2002). Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum. Gene Ther. 13, 1859-1871. (Pubitemid 35292681)
42. Siders, W.M., Halloran, P.J., and Fenton, R.G. (1996). Tran-scriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 56, 5638-5646. (Pubitemid 26422166)
43. Stritzker, J., Pilgrim, S., Szalay, A.A., and Goebel, W. (2008). Prodrug converting enzyme gene delivery by L. monocytogenes. BMC Cancer 8, 94.
44. Suzuki, E., Nishimatsu, H., Satonaka, H., et al. (2002). Angio-tensin II induces myocyte enhancer factor 2- and calcineurin/ nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes. Circ. Res. 90, 1004-1011. (Pubitemid 34633867)
45. Szala, S., Missol, E., Sochanik, A., and Strozyk, M. (1996). The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors. Gene Ther. 3, 1026-1031. (Pubitemid 26397479)
46. Szymczak, A.L., Workman, C.J., Wang, Y., et al. (2004). Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589-594. (Pubitemid 38585911)
47. Yang, S., and Haluska, F.G. (2004). Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J. Immunol. 172, 4599-4608. (Pubitemid 38375278)